CD274 and non-small cell lung carcinoma: In summary, a number of clinical trials are ongoing involving avelumab, toripalimab, tiragolumab or relatlimab in combination with or without chemotherapy and some studies aiming to explore safety and efficiency of PD-(L)1 in combination with lenvatinib, Poly ADP-Ribose Polymerase, APX005M, and GEN1046 for advanced or metastatic NSCLC.